Loading...

Gilead Sciences, Inc.

GILD•NASDAQ
Healthcare
Drug Manufacturers - General
$110.87
$0.20(0.18%)

Gilead Sciences, Inc. (GILD) Stock Overview

Explore Gilead Sciences, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B+

Score: 79.2/100

Key Financials

Market Cap137.9B
P/E Ratio23.03
EPS (TTM)$7.74
ROE0.32%

AI Price Forecasts

1 Week$111.75
1 Month$117.47
3 Months$119.44
1 Year Target$104.80

GILD Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Gilead Sciences, Inc. (GILD) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $104.80.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 23.03 and a market capitalization of 137.9B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Revenue Growth
6.04%
↑ 6.04%
Profit Growth
$4.79
↓ 91.53%
EPS Growth
$4.79
↓ 91.63%
Operating Margin
28.61%
↓ 78.15%
ROE
31.71%
↓ 91.53%
Dividend Yield
0.00%
↑ 2.94%

Analyst Recommendations

Strong Buy
0
Buy
12
Hold
2
Sell
0
Strong Sell
0

Price Targets

Low$71.00
Average$99.06
High$135.00

Company Profile

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.

CEO

Daniel P. O'Day

Employees

17,600

Headquarters

333 Lakeside Drive, Foster City, CA

Founded

1992

Frequently Asked Questions

;